Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
about
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexMet-HGF/SF signal transduction induces mimp, a novel mitochondrial carrier homologue, which leads to mitochondrial depolarizationThe Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinaseNeutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal modelsDisruption of epithelial cell-matrix interactions induces apoptosisDetection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reactionMonovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentBiology of MET: a double life between normal tissue repair and tumor progressionMet receptor tyrosine kinase: enhanced signaling through adapter proteinsDownregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma developmentEvidence for autocrine basis of transformation in NIH-3T3 cells transfected with met/HGF receptor geneNormal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factorc-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinomaGrowth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a structurally conserved putative zinc finger domainIdentification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases.Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1RCo-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiationHGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells.Deficient expression of mRNA for the putative inductive factor bone morphogenetic protein-7 in chemically initiated rat nephroblastomas.Expression of hepatocyte growth factor and c-MET in skull base chordoma.Actions of heparin that may affect the malignant process.Growth factors in inflammatory bowel disease.The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatmentc-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.Hepatocyte growth factor/scatter factor-induced intracellular signalling.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinaseNon-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.New insights into the biology of renal cell carcinomaInvasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma.Small cell lung cancer: from molecular biology to novel therapeutics.
P2860
Q24293027-56021A27-C3D3-45D5-A9F7-8D03F4E611D3Q24550994-C9DAE199-8CFA-4397-84A2-C488FCE14210Q24554529-53DF1790-BE5C-4FB6-AC66-5F98243A92EBQ24629814-ED570443-6031-4E72-AC67-09E8980B953EQ24673611-4EACD001-90F7-4FBB-A8F8-72B20AC9476DQ24803522-176C94F3-83B3-4C99-BED7-96C222CE6C1AQ27679191-CC787BF9-44EE-412C-990D-34E15B3B14E0Q28085247-B36B8638-C5DF-44CC-9C28-DAC4EFA806BBQ28140219-4F018DBD-6783-4ADB-A784-D4E7BCBE496BQ28214978-E648769A-6161-4F77-A03C-10BE86DFB4ABQ28297450-C0E6AFF4-BE25-4479-9580-B941118719EAQ28345285-FB8DC0D0-C914-4432-8CDB-8959A6A3267EQ28362076-D475B026-693E-460A-9380-5C82136E1AB8Q28593533-82E17580-8DBE-4B34-9391-390A58227F6EQ30168876-CBE2CA15-C6F8-4297-AF33-6809ECAF60E6Q30425784-32F89CB5-961A-4A62-96BE-89CA4DED9F5CQ30492361-11B00D01-9E95-4AF9-A944-035CE5AFF25BQ30534479-6138CE3C-9338-4F50-82E3-D76F3513FA18Q30929211-686F0C02-7207-4827-97A3-22973A90C7A5Q31978815-C3EC4DEF-865D-41D7-A912-EACD8138417BQ33272962-65926455-4F88-4D7E-9A31-695A11A43910Q33534337-D2278E02-3068-4569-B4AE-55369B989F0EQ33535516-045F0148-7618-49D1-9000-FC3D20BE38D2Q33536301-7D9FB44A-A80B-4A0E-8652-B506581FB86DQ33605698-C5E563F9-AA7B-443D-809B-031830CD3380Q33607965-777D3256-C827-41A8-8781-748B272F8592Q33622575-EAE83F59-FE1E-4AB8-86C1-60E032CEFD97Q33786959-8C17BDED-9CD1-4AEF-8493-8C413D5717FDQ33863966-4D24DB80-3D87-46EE-AB77-6173AD1EA631Q33880064-BADB6A65-99B6-404A-8997-CAFD1A19C93AQ33943764-C71EC300-1996-4195-B708-A90BF54D329EQ34236834-FC43EE44-8E38-47F8-B3F5-858E548465AAQ34393166-EECC9B81-C6F0-4B37-9B88-B10841302008Q34724977-205A6568-5E7A-4A03-9D3C-17ED64B28208Q34769614-B3EC54CA-8BEC-42C8-BFFE-71CE42FF2013Q35070072-65B212BC-63BC-4284-AAAC-7E710860E39FQ35180400-4E81CC14-333D-492A-9C30-AB351CA7FDFDQ35277738-F0B58888-797F-4DEA-93E2-7CC7AF0137BEQ35426283-CABA8737-98FA-4220-9D8D-BAD705555354Q35608984-DDDF5B86-57EE-4E8A-896F-A7BD6038A36D
P2860
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@ast
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@en
type
label
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@ast
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@en
prefLabel
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@ast
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@en
P2093
P2860
P356
P1476
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
@en
P2093
G F Vande Woude
M Bodescot
S Aaronson
T Nakamura
P2860
P304
P356
10.1128/MCB.12.11.5152
P407
P577
1992-11-01T00:00:00Z